NCT Number: NCT00038974
Hepatitis C Antiviral Resistance in African-Americans
This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–70 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
University of California, San Francisco, San Francisco, California, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion:
- Age between 18 and 70 years at screening
- Black/African American or White/Caucasian
- Born in the United States
- Quantifiable Serum HCV RNA
- Hepatitis C genotype 1
- Liver biopsy consistent with chronic hepatitis C
- Negative urine pregnancy test
- Males and Females must be using two reliable forms of effective contraception while on drug and during follow-up.
Exclusion:
- Previous treatment with interferon or ribavirin
- Positive test at screening for anti-HIV
- Positive test for HBsAg
- Alcohol consumption of more than two drinks/day
- History of other chronic liver disease
- Pregnant or breast-feeding women
- Male partners of women who are pregnant or contemplating pregnancy
- Neutrophil count <1000 cells/mm3
- Hgb <11 g/dl in women or 12 g/dl in men
- Platelet count <75,000 cells/mm3.
- Thalassemia, spherocytosis, history of GI bleeding or those at increased risk of anemia
- Serum creatinine level >1.5 times the upper limit of normal at screening or CrCl < 75cc/min
- Current dialysis
- Alcohol or drug abuse within 6 months
- Current (<6 months)severe psychiatric disorder
- History of immunologically mediated disease
- Decompensated liver disease
- High risk cardiovascular/coronary artery disease
- Severe seizure disorder or anticonvulsant use
- Solid organ or bone marrow transplantation
- Thyroid disease poorly controlled on prescribed medications
- History or other evidence of retinopathy
- Chronic use of oral steroids
- Inability or unwillingness to provide informed consent or abide by the study protocol
Treatment and study plan
Ribavirin
DrugPrimary outcomes
-
Sustained Virologic Response (SVR)
Time frame: 24 weeks after therapy is discontinued
The primary end point of therapy was an SVR that was definied as the absences of detectable HCV RNA in serum 24 weeks after therapy was stopped.
Sponsors and collaborators
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nih
Collaborators
- Hoffmann-La Roche
- National Cancer Institute (NCI)
- National Center for Advancing Translational Sciences (NCATS)
- National Institute on Minority Health and Health Disparities (NIMHD)
Registry information
Official study title
Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C)
Important dates
- Study start
- 2002
- Primary completion
- 2004
- Study completion
- 2005
- First posted
- Jun 10, 2002
- Registry last updated
- Aug 3, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Reaching mEthadone Users Attending Community pHarmacies With HCV
NCT03935906
Blood-Borne Infections, Communicable Diseases
Melbourne, Australia
View Trial DetailsEpidemiology, Infectivity and Natural History of Hepatitis C Virus Infection
NCT00004850
Blood-Borne Infections, Communicable Diseases
Bethesda, Maryland, United States
View Trial DetailsTele-Harm Reduction
NCT05208697
Blood-Borne Infections, Communicable Diseases
Fort Lauderdale, Florida, United States
View Trial DetailsExpanding the Pool in Orthotopic Heart Transplantation
NCT03222531
Blood-Borne Infections, Cardiac Transplant
Pittsburgh, Pennsylvania, United States
View Trial Details